title: [The use of agomelatine (valdoxan) in gambling therapy: a pilot study].
abstract: OBJECTIVE
  To study the antidepressant agomelatine (M1/M2 agonist and 5-HT2C antagonist) in pathological gambling (PG) (ICD-10 item F63.0).
  
  
  METHODS
  An open label 8-week trial was carried out in 22 outpatients (17 male and 5 female, mean age 38±7). PG severity was assessed by the Yale-Brown Obsessive-Compulsive Scale adapted for Pathological Gambling (PG-YBOCS). Anxiety and depression level was measured by the Hospital Anxiety Depression Scale (HADS).
  
  
  RESULTS
  Agomelatine significantly decreased PG-YBOCS scores from the second week of the trial (12.6±3.0 compared to 24.2±2.1 at baseline, p<0.05). In the end of the trial, PG-YBOCS score decreased to 5.3. The total HADS score decreased significantly in the end of the study (from 23.6±2.9 to 11.4±1.9, p<0.05). There was an improvement in behavior as well.
  
  
  CONCLUSIONS
  Thus, agomelatine has demonstrated efficacy in PG patients.
authors.affiliation: St. Petersburg State University, Medical Faculty, Department of Psychiatry and Addictions, Mechnikov Nord-West Medical University, Department of Psychiatry and Addictions, St. Petersburg, Sechenov Institute of Evolutionary Physiology and Biochemistry, Laboratory of Behaviour Neurophysiology and Pathology, St. Petersburg.
authors.forename: A Yu
authors.initials: AY
authors.lastname: Egorov
mesh_terms: D000081:Acetamides / Q000627:therapeutic use*; D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001007:Anxiety / Q000175:diagnosis; D005260:Female; D005715:Gambling / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D044122:Receptor, Melatonin, MT1 / Q000037:antagonists & inhibitors*; D044123:Receptor, Melatonin, MT2 / Q000037:antagonists & inhibitors*; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult; D009281:Naphthalenes
chemical_list: D000081:Acetamides; D000928:Antidepressive Agents; D044122:Receptor, Melatonin, MT1; D044123:Receptor, Melatonin, MT2; D058830:Serotonin 5-HT2 Receptor Antagonists; C084711:agomelatine; D009281:Naphthalenes